Adverse events
Mild injection site reaction, decreased appetite, fatigue, myalgia, chills and anemia possibly related to ARQ 501 therapy
At doses of 390-550 mg/m2, reversible hemolytic anemia and hyperbilirubinemia noted
No signs of myelosuppression
Events consistent with preclinical toxicology